search icon
      blog search icon

      BMRN Stock Price History and Quote Analysis: Insights for Investors

      BioMarin Pharmaceutical Inc.



      1.34 (1.47%)

      At Close: 4:00 PM

      BMRN Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      BMRN Stock Price Today

      BioMarin Pharmaceutical Inc. (BMRN) stock rallied over 1.47% intraday to trade at $92.42 a share on NASDAQ. The stock opened with a loss of -10.45% at $81.56 and touched an intraday high of $81.93, rising 1.47% against the last close of $91.08. The BioMarin Pharmaceutical Inc. in stock market went to a low of $80.24 during the session.

      BMRN Stock Snapshot


      Prev. Close

      17.41 Billion

      Market Cap


      Day Low




      Number of Shares


      Day High


      P/E ratio


      EPS (TTM)


      Cash Flow per Share


      Free Float in %


      Book Value



      BMRN Stock Price History Chart


      Contact Details

      770 Lindaro Street
      San Rafael, CA 94901


      Contact #:415 506 6700

      Company Information



      Sales or Revenue$2.31 Billion

      5Y Sales Change9.30%

      Fiscal Year EndsDec. 2022



      About Company

      BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.


      Frequently Asked Questions


      What is the current BioMarin Pharmaceutical Inc. (BMRN) stock price?

      BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock price is $92.42 in the last trading session. During the trading session, BMRN stock reached the peak price of $81.93 while $80.24 was the lowest point it dropped to. The percentage change in BMRN stock occurred in the recent session was 1.47% while the dollar amount for the price change in BMRN stock was $1.34.


      BMRN's industry and sector of operation?

      The NASDAQ listed BMRN is part of Biotechnology industry that operates in the broader Healthcare sector. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.


      Who are the executives of BMRN?

      Ms. Erin Burkhart
      Group Vice President & Chief Accounting Officer
      Traci McCarty
      Vice President of Investor Relations
      Ms. Humaira Serajuddin
      Senior Vice President & Chief Marketing Officer
      Mr. Philip Lo Scalzo
      Senior Vice President & Chief Compliance Officer


      How BMRN did perform over past 52-week?

      BMRN's closing price is 0.35% higher than its 52-week low of $80.24 where as its distance from 52-week high of $117.77 is -0.19%.


      How many employees does BMRN have?

      Number of BMRN employees currently stands at N/A. BMRN operates from 770 Lindaro Street, San Rafael, CA 94901, US.


      Link for BMRN official website?

      Official Website of BMRN is:


      How do I contact BMRN?

      BMRN could be contacted at phone #415 506 6700 and can also be accessed through its website. BMRN operates from 770 Lindaro Street, San Rafael, CA 94901, US.


      How many shares of BMRN are traded daily?

      BMRN stock volume for the day was 2224338.00 shares. The average number of BMRN shares traded daily for last 3 months was 1.59 Million.


      What is the market cap of BMRN currently?

      The market value of BMRN currently stands at $17.41 Billion with its latest stock price at $92.42 and N/A of its shares outstanding.